Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Apr;13(4):523-8.
doi: 10.1111/j.1365-2125.1982.tb01415.x.

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man

A K Azadkhan et al. Br J Clin Pharmacol. 1982 Apr.

Abstract

1 We have investigated the disposition and metabolism of sulphasalazine (SASP) in eight adults with and without inflammatory bowel disease. 2 SASP is poorly absorbed (less than 12%) and the half-time measured in the serum, 10.2 h, is probably the half-time of absorption and therefore an overestimate of the true half-time. The apparent volume of distribution is low (less than 9 l). Renal and biliary clearance rates are low (5.5 and 2.1 ml min-1 respectively) probably due to a high degree of protein binding. Of the absorbed SASP, two thirds is excreted in the urine and one third in the bile. 3 Most of the SASP reaches the colon and is there split by bacteria, forming sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA). 4 SP is almost completely absorbed and, with its metabolites, is excreted in the urine (SP renal clearance rate 32.1 ml min-1). There is no enterohepatic recirculation. 5 Of the 5-ASA released in the colon at least 25% is absorbed and rapidly eliminated in the urine after acetylation. At least 50% is eliminated in the faeces. 6 There are no differences in disposition characteristics when comparing patients with and without inflammatory bowel disease but the metabolism of SASP is markedly reduced in patients taking antibiotics and after removal of the large bowel.

PubMed Disclaimer

References

    1. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539-51 - PubMed
    1. Gastroenterology. 1973 Feb;64(2):240-5 - PubMed
    1. Acta Pharm Suec. 1973 Mar;10(1):87-92 - PubMed
    1. Acta Pharm Suec. 1973 May;10(2):107-10 - PubMed
    1. Acta Pharm Suec. 1973 May;10(2):153-5 - PubMed

Publication types

LinkOut - more resources